AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12675760 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 ml of 1:1000 nebulized adrenaline
Number of subjects: 75
Study 12675760 — intervention group
Group type: COMPARATOR
Intervention: 2 ml of nebulized normal saline
Number of subjects: 75
Study 12675760 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized adrenaline
Number of subjects: 75
Study 10744272 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive fluid resuscitation strategy
Number of subjects: 34
Study 9186254 — intervention group
Group type: EXPERIMENTAL
Intervention: Childhood-onset epilepsy (epilepsy only)
Number of subjects: 100
Study 9186254 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiepileptic polytherapy
Number of subjects: 100
Study 9186254 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuing seizures
Number of subjects: 100
Study 9186254 — intervention group
Group type: COMPARATOR
Intervention: Random controls
Number of subjects: 100
Study 9186254 — intervention group
Group type: COMPARATOR
Intervention: Employee controls
Number of subjects: 100
Study 1546154 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide
Number of subjects: 173
Study 1546154 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 173
Study 1546154 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 173
Study 28613407 — intervention group
Group type: EXPERIMENTAL
Intervention: iCBT intervention group
Number of subjects: 80
Study 28613407 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study 29986695 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-generated individualized feedback letters at baseline, month 3, and month 6.
Number of subjects: 1648
Study 29986695 — intervention group
Group type: COMPARATOR
Intervention: Assessment only (Control group).
Number of subjects: 1648
Study 27276401 — intervention group
Group type: EXPERIMENTAL
Intervention: α-lipoic acid (ALA) at 600-1800 mg
Number of subjects: 22
Study 27276401 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 25876343 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive treatment (acupoint injection + neural electrical stimulation)
Number of subjects: 183
Study 25876343 — intervention group
Group type: COMPARATOR
Intervention: Acupoint injection
Number of subjects: 183
Study 25876343 — intervention group
Group type: COMPARATOR
Intervention: Neural electrical stimulation
Number of subjects: 183
Study 25876343 — intervention group
Group type: COMPARATOR
Intervention: Swallowing training
Number of subjects: 183
Study 25876343 — intervention group
Group type: COMPARATOR
Intervention: Blank control group
Number of subjects: 183
Study 22832365 — intervention group
Group type: EXPERIMENTAL
Intervention: Decompressive surgery (DS) for malignant middle cerebral artery infarcts
Number of subjects: 31
Study 20458350 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (5 mg/day for 4 months)
Number of subjects: 44
Study 20458350 — intervention group
Group type: COMPARATOR
Intervention: Alfacalcidol (0.5 microg/day for 4 months)
Number of subjects: 44
Study 20458350 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (5 mg/day for 2 months after crossover)
Number of subjects: 44
Study 20458350 — intervention group
Group type: COMPARATOR
Intervention: Alfacalcidol (0.5 microg/day for 2 months after crossover)
Number of subjects: 44
Study 18479174 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (rHuEPO)
Number of subjects: 88
Study 16077385 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (1 mg . kg ‐1) during induction of anesthesia
Number of subjects: 34
Study 16077385 — intervention group
Group type: COMPARATOR
Intervention: Control group (no dexamethasone)
Number of subjects: 34
Study 12663440 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinine (30 mg/kg/day continuous intravenous infusion) in combination with induction chemotherapy (idarubicine and cytarabine)
Number of subjects: 425
Study 12663440 — intervention group
Group type: COMPARATOR
Intervention: Quinine
Number of subjects: 425
Study 12663440 — intervention group
Group type: COMPARATOR
Intervention: Induction chemotherapy (idarubicine and cytarabine) with or without quinine
Number of subjects: 425
Study 10731406 — intervention group
Group type: EXPERIMENTAL
Intervention: JPEG compression ratio 10:1
Number of subjects: 48
Study 10731406 — intervention group
Group type: EXPERIMENTAL
Intervention: JPEG compression ratio 16:1
Number of subjects: 48
Study 10731406 — intervention group
Group type: EXPERIMENTAL
Intervention: JPEG compression ratio 6:1
Number of subjects: 48
Study 10731406 — intervention group
Group type: COMPARATOR
Intervention: JPEG compression ratio 1:1 (uncompressed)
Number of subjects: 48
Study 8707499 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 1643937 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-hour oxygen withdrawal
Number of subjects: 6
Study 1643937 — intervention group
Group type: COMPARATOR
Intervention: Routine therapy
Number of subjects: 6
Study 6439408 — intervention group
Group type: EXPERIMENTAL
Intervention: DDP-MECY (methotrexate-leucovorin plus cyclophosphamide)
Number of subjects: 33
Study 6439408 — intervention group
Group type: COMPARATOR
Intervention: DDP-CHAD (cyclophosphamide, hexamethylmelamine, doxorubicin, and DDP)
Number of subjects: 33
Study 6439408 — intervention group
Group type: EXPERIMENTAL
Intervention: DDP-MECY
Number of subjects: 33
Study 6439408 — intervention group
Group type: COMPARATOR
Intervention: DDP-CHAD
Number of subjects: 33
Study 31361094 — intervention group
Group type: EXPERIMENTAL
Intervention: deoxyribonucleate sodium (75 mg via intramuscular injection every 48 hours for 1 month)
Number of subjects: 62
Study 31361094 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard therapy without deoxyribonucleate sodium)
Number of subjects: 62
Study 31361094 — intervention group
Group type: EXPERIMENTAL
Intervention: deoxyribonucleate sodium
Number of subjects: 62
Study 27964837 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin plus basal insulin (glargine once daily)
Number of subjects: 279
Study 27964837 — intervention group
Group type: COMPARATOR
Intervention: Basal-bolus regimen (glargine once daily and rapid-acting insulin before meals)
Number of subjects: 279
Study 25942458 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir 400 mg two times a day for 7 days
Number of subjects: 24
Study 25942458 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg once a day for 7 days
Number of subjects: 24
Study 25942458 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of atorvastatin 20 mg once a day + raltegravir 400 mg two times a day for 7 days
Number of subjects: 24
Study 24991090 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir (RAL)
Number of subjects: 37
Study 24991090 — intervention group
Group type: COMPARATOR
Intervention: PI/NNRTI
Number of subjects: 37
Study 22029869 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-haptic angulated (FA) intraocular lens (IOL)
Number of subjects: 40
Study 22029869 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-haptic non-angulated (TNA) intraocular lens (IOL)
Number of subjects: 40
Study 20137416 — intervention group
Group type: EXPERIMENTAL
Intervention: levofloxacin 0.5%
Number of subjects: 150
Study 20137416 — intervention group
Group type: COMPARATOR
Intervention: gatifloxacin 0.3%
Number of subjects: 150
Study 20137416 — intervention group
Group type: COMPARATOR
Intervention: levofloxacin 0.3%
Number of subjects: 150
Study 17352026 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose regimen (group A): omeprazole 20 mg b.i.d, clarithromycin 250 mg b.i.d, amoxicillin 500 mg b.i.d
Number of subjects: 160
Study 17352026 — intervention group
Group type: COMPARATOR
Intervention: High-dose regimen (group B): omeprazole 20 mg b.i.d, clarithromycin 500 mg b.i.d, amoxicillin 1000 mg b.i.d
Number of subjects: 160
Study 15449576 — intervention group
Group type: EXPERIMENTAL
Intervention: Special nutritional formula providing 480 kcal, 31 g proteins, 120 IU vitamin E, 3.8 microg vitamin B12, 400 microg folic acid, 10(9) cfu Lactobacillus paracasei (NCC 2461), and 6 g of fructo‐oligosaccharides
Number of subjects: 60
Study 15449576 — intervention group
Group type: COMPARATOR
Intervention: Nonsupplemented individuals
Number of subjects: 60
Study 11678298 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg methylprednisolone acetate injection with local anesthetic (group A)
Number of subjects: 20
Study 11678298 — intervention group
Group type: COMPARATOR
Intervention: Physical therapy measures plus nonsteroidal anti‐inflammatory drugs (group B)
Number of subjects: 20
Study 9395778 — intervention group
Group type: EXPERIMENTAL
Intervention: Physostigmine salicylate, 8 mg/ml, one drop instilled at 7 AM and repeated on alternate hours throughout the day
Number of subjects: 20
Study 9395778 — intervention group
Group type: EXPERIMENTAL
Intervention: Physostigmine salicylate, 8 mg/ml
Number of subjects: 20
Study 7734028 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosulpiride (75 mg/day for 20 days)
Number of subjects: 30
Study 7734028 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 2438613 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined chemo‐radiotherapy (2 X COPP/ABVD + 40 Gy EF)
Number of subjects: 358
Study 2438613 — intervention group
Group type: COMPARATOR
Intervention: Combined chemo‐radiotherapy (2 X COPP/ABVD + 20 Gy IF)
Number of subjects: 358
Study 2438613 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (3 X COPP/ABVD) followed by consolidation by radiotherapy (20 Gy IF)
Number of subjects: 358
Study 2438613 — intervention group
Group type: COMPARATOR
Intervention: Induction chemotherapy (3 X COPP/ABVD) followed by consolidation by chemotherapy (1 X COPP/ABVD)
Number of subjects: 358
Study 2438613 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvage therapy (radiotherapy in case of persisting nodal disease; chemotherapy with 4 X CEVD in case of persisting disseminated disease)
Number of subjects: 358
Study 2438613 — intervention group
Group type: EXPERIMENTAL
Intervention: Consolidation therapy
Number of subjects: 358
Study 29856832 — intervention group
Group type: EXPERIMENTAL
Intervention: Modest fixed-value payment per exercise session
Number of subjects: 0
Study 29856832 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced incentives to exercise more frequently
Number of subjects: 0
Study 29856832 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced financial incentive to increase exercise duration
Number of subjects: 0
Study 29856832 — intervention group
Group type: COMPARATOR
Intervention: Standard payment group
Number of subjects: 0
Study 29856832 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic fitness
Number of subjects: 0
Study 29856832 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin sensitivity and body composition
Number of subjects: 0
Study 28452705 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal saline solution nasal-pharyngeal irrigation (NSNPI) for 30 days
Number of subjects: 50
Study 28452705 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate nasal spray (FPNS) for 30 days
Number of subjects: 50
Study 24646362 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyphenon E 400 mg, 600 mg, and 800 mg (combined)
Number of subjects: 34
Study 24646362 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyphenon E (all doses combined)
Number of subjects: 34
Study 24646362 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 23513000 — intervention group
Group type: EXPERIMENTAL
Intervention: HD ProCore(™) needle
Number of subjects: 36
Study 23513000 — intervention group
Group type: COMPARATOR
Intervention: Standard 22-gauge needle
Number of subjects: 36
Study 22055587 — intervention group
Group type: EXPERIMENTAL
Intervention: PEI-RFA
Number of subjects: 90
Study 22055587 — intervention group
Group type: COMPARATOR
Intervention: RFA alone
Number of subjects: 90
Study 22055587 — intervention group
Group type: COMPARATOR
Intervention: PEI alone
Number of subjects: 90
Study 19004596 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular acupuncture as an adjunct to methadone detoxification
Number of subjects: 83
Study 19004596 — intervention group
Group type: COMPARATOR
Intervention: Standard methadone detoxification treatment (Control)
Number of subjects: 83
Study 17531569 — intervention group
Group type: EXPERIMENTAL
Intervention: Very high hs‐CRP levels (>7.5 mg/L)
Number of subjects: 80
Study 17531569 — intervention group
Group type: COMPARATOR
Intervention: Very low hs‐CRP levels (<=1 mg/L)
Number of subjects: 80
Study 15620225 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodic waveforms
Number of subjects: 5
Study 15620225 — intervention group
Group type: EXPERIMENTAL
Intervention: Single repetitions of a piece of the waveform
Number of subjects: 5
Study 15620225 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory sensory memory
Number of subjects: 5
Study 11729476 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (M-VAC: methotrexate, vinblastine, adriamycin, cisplatin)
Number of subjects: 0
Study 11729476 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy
Number of subjects: 0
Study 11729476 — intervention group
Group type: COMPARATOR
Intervention: Radical cystectomy
Number of subjects: 0
Study 9930484 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold blood cardioplegia followed by warm reperfusion
Number of subjects: 105
Study 9930484 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold crystalloid cardioplegia followed by warm reperfusion
Number of subjects: 105
Study 9930484 — intervention group
Group type: COMPARATOR
Intervention: Cold blood cardioplegia with no reperfusion
Number of subjects: 105
Study 8683846 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vitamin A capsules given to 42 children
Number of subjects: 101
Study 8683846 — intervention group
Group type: COMPARATOR
Intervention: Control group of 53 children
Number of subjects: 101
Study 2181843 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical treatment
Number of subjects: 797
Study 2181843 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment (coronary bypass surgery)
Number of subjects: 797
Study 2181843 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal thoracic (mammary) artery grafting
Number of subjects: 797
Study 2181843 — intervention group
Group type: COMPARATOR
Intervention: Vein grafts only
Number of subjects: 797
Study 2181843 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment only
Number of subjects: 797
Study 7000170 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir 2% ointment 5 times a day
Number of subjects: 60
Study 7000170 — intervention group
Group type: COMPARATOR
Intervention: Idoxuridine 1% ointment 5 times a day
Number of subjects: 60
Study 30813612 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy restricted diets and/or exercise interventions
Number of subjects: 221
Study 28814158 — intervention group
Group type: EXPERIMENTAL
Intervention: oxymorphone patches + capsaicin
Number of subjects: 15
Study 28814158 — intervention group
Group type: COMPARATOR
Intervention: oxymorphone patches - capsaicin
Number of subjects: 15
Study 25885807 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured smoking cessation program delivered by trained ambulatory pharmacists (at least four sessions face-to-face)
Number of subjects: 0
Study 25885807 — intervention group
Group type: COMPARATOR
Intervention: Unstructured brief smoking cessation advice (5 to 10 min) given by the pharmacist
Number of subjects: 0
Study 25885807 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups offered nicotine replacement therapy if feasible
Number of subjects: 0
Study 25582987 — intervention group
Group type: EXPERIMENTAL
Intervention: MobileMums
Number of subjects: 263
Study 25582987 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 263
Study 22637738 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertrophy resistance training (HRT) - 2 sets, 10-12 repetitions, 70% of one-repetition maximum (1-RM)
Number of subjects: 32
Study 22637738 — intervention group
Group type: COMPARATOR
Intervention: Endurance resistance training (ERT) - 2 sets, 25-30 repetitions, 40% of one-repetition maximum (1-RM)
Number of subjects: 32
Study 22637738 — intervention group
Group type: EXPERIMENTAL
Intervention: Both HRT and ERT (combined with aerobic exercise training)
Number of subjects: 32
Study 22008920 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan
Number of subjects: 45
Study 22008920 — intervention group
Group type: COMPARATOR
Intervention: Losartan
Number of subjects: 45
Study 18074296 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate
Number of subjects: 13
Study 18074296 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate + Protein
Number of subjects: 13
Study 18074296 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 16468059 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-parameter models
Number of subjects: 17
Study 16468059 — intervention group
Group type: COMPARATOR
Intervention: Two-parameter models
Number of subjects: 17
Study 16468059 — intervention group
Group type: EXPERIMENTAL
Intervention: Critical velocity (CV)
Number of subjects: 17
Study 16468059 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of CV with other parameters
Number of subjects: 17
Study 14649401 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin treatment maintained
Number of subjects: 70
Study 14649401 — intervention group
Group type: COMPARATOR
Intervention: Warfarin stopped prior to surgery
Number of subjects: 70
Study 11030374 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral food challenges with cow's milk, hen's egg, wheat, and soy
Number of subjects: 204
Study 11030374 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral medication
Number of subjects: 204
Study 11030374 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral medication
Number of subjects: 204
Study 11030374 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific IgE levels
Number of subjects: 204
Study 11030374 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient history of food allergy
Number of subjects: 204
Study 11030374 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive patient history and high specific IgE levels
Number of subjects: 204
Study 11030374 — intervention group
Group type: EXPERIMENTAL
Intervention: Establishing intravenous access
Number of subjects: 204
Study 9563239 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group therapy (CBT)
Number of subjects: 0
Study 7812205 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction treatment with human lymphoblastoid IFN alpha-n1, 3 MU/mq daily for a median of 5.7 months
Number of subjects: 89
Study 7812205 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance treatment with human lymphoblastoid IFN alpha-n1, 3 MU/mq weekly
Number of subjects: 89
Study 7812205 — intervention group
Group type: EXPERIMENTAL
Intervention: Retreatment with human lymphoblastoid IFN alpha-n1 after relapse
Number of subjects: 89
Study 7812205 — intervention group
Group type: EXPERIMENTAL
Intervention: Third induction treatment with human lymphoblastoid IFN alpha-n1
Number of subjects: 89
Study 7812205 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 89
Study 3287839 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-week treatment with pivampicillin plus pivmecillinam
Number of subjects: 61
Study 3287839 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-week treatment with pivampicillin plus pivmecillinam
Number of subjects: 61
Study 3287839 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 61
Study 30300870 — intervention group
Group type: COMPARATOR
Intervention: Mindfulness only group (n = 27)
Number of subjects: 101
Study 30300870 — intervention group
Group type: COMPARATOR
Intervention: Mindfulness + plain-text reminder group (n = 24)
Number of subjects: 101
Study 30300870 — intervention group
Group type: COMPARATOR
Intervention: Mindfulness + enhanced text reminder with animal meme group (n = 25)
Number of subjects: 101
Study 30300870 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 25)
Number of subjects: 101
Study 28188585 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal behavior change strategies (social support, friendly social comparison; yes)
Number of subjects: 102
Study 28188585 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapersonal behavior change strategies (goal setting, barriers management; yes)
Number of subjects: 102
Study 28188585 — intervention group
Group type: COMPARATOR
Intervention: No interpersonal behavior change strategies (no)
Number of subjects: 102
Study 28188585 — intervention group
Group type: COMPARATOR
Intervention: No intrapersonal behavior change strategies (no)
Number of subjects: 102
Study 26601555 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (1-2%)
Number of subjects: 57
Study 26601555 — intervention group
Group type: COMPARATOR
Intervention: Propofol (0.2-0.5 mg/kg)
Number of subjects: 57
Study 23188886 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent‐Child Interaction Therapy (PCIT)
Number of subjects: 44
Study 21480412 — intervention group
Group type: EXPERIMENTAL
Intervention: Saffron (100 mg daily for 6 weeks)
Number of subjects: 45
Study 21480412 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 18453877 — intervention group
Group type: EXPERIMENTAL
Intervention: semiliquid diet
Number of subjects: 60
Study 18453877 — intervention group
Group type: COMPARATOR
Intervention: clear feeds
Number of subjects: 60
Study 16547654 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication with beta blockers
Number of subjects: 429
Study 16547654 — intervention group
Group type: EXPERIMENTAL
Intervention: Class III antiarrhythmic agents (sotalol and amiodarone)
Number of subjects: 429
Study 16547654 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival rate
Number of subjects: 429
Study 16547654 — intervention group
Group type: EXPERIMENTAL
Intervention: Sudden death
Number of subjects: 429
Study 16547654 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-sudden cardiac causes of death
Number of subjects: 429
Study 16547654 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-cardiac fatal events
Number of subjects: 429
Study 16547654 — intervention group
Group type: COMPARATOR
Intervention: Structural heart disease
Number of subjects: 429
Study 16547654 — intervention group
Group type: COMPARATOR
Intervention: Left ventricular ejection fraction
Number of subjects: 429